HopeStage
Back to all studies
CompletedNCT01121042

Ondansetron or placebo added to treatment for schizophrenia

About this titleRead the official source — NCT01121042
Medication studyAges 18–65Australia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
MelbourneSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2010
Recruitment status
Completed
Enrollment listed in the registry
85
Sponsor
Bayside Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Australia
Age range
From 18 Years to 65 Years
Official registry ID
NCT01121042
Official title
Show the full official title

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Melbourne

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Bayside Health.

Did this study involve medication?

Yes. The study involved medication, including Ondansetron and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies